HOME >> MEDICINE >> NEWS
GroPep starts Phase 1 infertility trial

GroPep's program - to develop a treatment for a condition that potentially causes 50% of all miscarriages - reached a major milestone today with commencement of recruitment of healthy women volunteers into a Phase 1 trial of its infertility drug, PV903.

The drug is targeted to treat recurrent miscarriages caused by an abnormal immune response to the foetus a condition for which there is no current treatment.

The market for a drug to treat this condition is estimated to be up to US$750 million annually.

Listed biopharmaceutical company GroPep Limited (ASX:GRO) announced today that it will commence a Phase 1 trial of its infertility drug PV903. The trial, which will be conducted under the Therapeutic Goods Administration Clinical Trial Notification scheme, was approved by the Royal Adelaide Hospital Research Ethics Committee.

Recruitment will begin immediately to allow medical screening and enrolment of the first cohort of subjects in mid-February 2006. The results of the trial should be known in late 2006, depending on recruitment rate.

The trial, conducted at the CMAX Adelaide-based facilities, involves healthy female volunteers each receiving a single administration of PV903 gel (or placebo) as they are enrolled sequentially into three groups with the PV903 dose escalating between groups. A total of 36 volunteers will complete the trial. The objectives of the trial are to evaluate the safety and tolerability of vaginally administered PV903 gel, and to determine whether PV903 has effects on vaginal immune cells in a manner consistent with its proposed role in treating immunebased infertility.

Over 50% of miscarriages have no apparent explanation and some scientists believe that women who suffer from repeated miscarriage have an immune system that attacks the embryo as "foreign". PV903 is a recombinant version of a protein that is naturally found in semen and thought to be re
'"/>

Contact: Mr Tony Mitchell
61-283-547-700
Research Australia
9-Jan-2006


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep completes final milestone of the path malaria vaccine initiative
3. GroPep to pursue promising asthma drug following preclinical study results
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Coffee jump-starts short-term memory
7. Epidemiology in Europe: the problem starts in childhood
8. GSK announces launch of largest ever Phase III trial in lung cancer treatment
9. Phase II study shows combination improves survival of metastatic melanoma patients
10. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
11. Drug combination proves effective against myeloma in Phase I trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... ... September 01, 2020 , ... Dr. Kiran Gill is a ... of the face, breast, and body. In 2018, she founded Aesthetics in Plastic ... and aesthetic practice in Southwest Florida. Dr. Gill and her team offer surgical ...
(Date:8/31/2020)... ... August 31, 2020 , ... Ocean Springs, Mississippi-based ... to medical first responders across the United States. Since the start of the ... equipment (PPE) medical centers , hospitals , firefighters , and ...
(Date:8/31/2020)... , ... August 31, 2020 , ... ... support services to dental groups in the United States, today announced the grand ... of Beaumont, CA. , Patients will enjoy convenient hours, a comfortable office, ...
(Date:8/31/2020)... ... August 31, 2020 , ... Dr. Chang has over ... autism and other developmental disabilities, as well as supporting staff in caring for ... autism, school consultation, and staff development. She joined the company in 2015 as ...
(Date:8/28/2020)... ... 28, 2020 , ... WHAT , Hespiro™ is a new ... conditions, including COVID-19, while reducing the need for scarce mechanical ventilators. It not ... and scrubs it free of carbon dioxide in a completely closed “rebreather” system, ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... , ... August 27, 2020 , ... The GHT ... of its fundraising initiative for Feeding San Diego with a press conference ... GHT Companies presents the final check of $5,000.00+ representing an overall donation result exceeding ...
(Date:8/26/2020)... , ... August 26, 2020 ... ... of Eurofins BioPharma Services, Laboratory Testing division, expands its technology footprint with ... of Flow Cytometry platforms available. With industry-leading biomarker solutions, complemented with traditional ...
(Date:8/26/2020)... N.D. (PRWEB) , ... August 26, 2020 , ... As ... familiar with the daily routine for preventing the Coronavirus. Wear a mask, keep your ... and fiber advocate Dr. Denis Burkitt said it best in 1977, “How much better ...
Breaking Medicine Technology:
Cached News: